Weekly Recap | Summit Therapeutics +1.87%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.The Week
Summit Therapeutics (SMMT) rose 1.87% on the week to $16.33, while the S&P 500 lost 2.68%, putting the stock about 4.55 percentage points ahead of the benchmark. Trading was choppy, with a 14.13% intraweek range: shares closed Monday at $14.80, climbed to $15.80 on Tuesday and $16.17 on Wednesday, dropped to $14.19 on Thursday, then rebounded to finish Friday at $16.33 after touching $16.36 intraday.
Key Events
The main story this week was the third-quarter earnings release. On 5 November, Summit Therapeutics reported a quarterly loss on higher R&D spending, with a net loss of $208.4m and EPS of -$0.26, while revenue came in at zero for the period. The 10-Q summary and 8-K filing released the same day confirmed the same financials. The shares moved higher in subsequent sessions, climbing more than 10.5% intraday on 4 November and more than 8% on 6 November. A 424B7 prospectus supplement also landed during the week and counts as a material filing.
Analyst Ratings
As of the latest data, 17 firms cover the stock: 10 rate it buy, 1 overweight and 6 hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target sits at about $30.14, roughly 84.54% above the spot price of $16.33. Targets range from $11.873 to $43.640, reflecting a wide dispersion. The stock ranks 46th among 510 biotechnology companies in its industry peer set.
The Week Ahead
Macro data dominates the coming week: US CPI and core CPI land on 10 November, alongside the NFIB Small Business Optimism Index, keeping the focus on inflation. Company-specific reporting is not due until the FY2026 annual results on 23 February 2027, where the market is looking for full-year EPS of -$1.1491 on revenue estimated at $3.96m.
In Short
The buy consensus and a target price more than 80% above spot set up a valuation tension, while the latest session shows large- and medium-lot orders as net buyers even as the company remains pre-revenue and losses are still tied to R&D. What to watch next is the read-through from inflation prints to growth names, and the annual results in February as a check on the loss trajectory.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.